IP Library Patent Application 10483993
Patent Application
App. No. 10/483,993

Remedies for mammary cancer

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
10/483,993
Abstract

Provided is a remedy for cancer which remedy is specific to cancer tissue and has therapeutic effects on mammary cancer. The remedy is available by associating an antitumor substance with a human monoclonal antibody having amino acid sequences of SEQ. ID. NOS. 1, 2 and 3 of Sequence Listing in hypervariable regions of a heavy chain and amino acid sequences of SEQ. ID. NOS. 4, 5 and 6 of Sequence Listing in hypervariable regions of a light chain by attaching the antibody to a liposome having the antitumor substance encapsulated therein.

Claims (13)

1 . A remedy for mammary cancer comprising a human monoclonal antibody having amino acid sequences of SEQ. ID. NOS. 1, 2 and 3 of Sequence Listing in hypervariable regions of a heavy chain and amino acid sequences of SEQ. ID. NOS. 4, 5 and 6 of Sequence Listing in hypervariable regions of a light chain; and an antitumor substance associated with the antibody.

2 . A remedy for mammary cancer of claim 1 , wherein the monoclonal antibody has a heavy chain variable region containing an amino acid sequence of SEQ. ID No. 7 of Sequence Listing and a light chain variable region containing an amino acid sequence of SEQ. ID No. 8 of Sequence Listing.

3 . A remedy for mammary cancer of claim 1 , wherein the antitumor substance has been associated with the antibody by binding the antibody to the surface of a liposome having the antitumor substance encapsulated therein.

4 . A mammary cancer of claim 3 , wherein the antibody has been bound to the surface of the liposome by attaching via a thioether group the antibody to the liposome having a lipid end partially maleimidated.

5 . A remedy for mammary cancer of claim 4 , wherein 0.1 to 2 mole % of the antibody has been bound to 1 mole of the maleimidated lipid.

6 . A remedy for mammary cancer of claim 4 , wherein the antibody has been bound to the surface of the liposome by causing the maleimide-containing liposome to react with a sulfur-containing group derived from the antibody to form a thioether bond.

7 . A remedy for mammary cancer of claim 3 , wherein to the surface of the liposome, a compound containing a polyalkyleneglycol portion has been bound further.

8 . A remedy for mammary cancer of claim 7 , wherein 15 to 50 mole % of the compound containing a polyalkyleneglycol portion has been bound to 1 mole of the maleimidated lipid contained in the liposome.

9 . A remedy for mammary cancer of claim 7 , wherein the compound containing a polyalkyleneglycol portion has been bound to the surface of the liposome by causing the maleimide group of the maleimidated lipid to react with the compound containing a polyalkyleneglycol portion added with a thiol group.

10 . A remedy for mammary cancer of claim 7 , wherein the polyalkyleneglycol portion is a polyethyleneglycol portion.

11 . A remedy for mammary cancer of claim 10 , wherein the compound containing a polyalkyleneglycol portion has two polyethyleneglycol portions.

12 . A remedy for mammary cancer of claim 10 , wherein the polyethyleneglycol portion has a molecular weight of from 2,000 to 7,000 daltons.

13 . A remedy for mammary cancer of claim 1 , wherein the antibody is an F(ab′) 2 fragment.

Assignments (2)
CHANGE OF NAME Recorded Apr 17, 2008
From: MITSUBISHI PHARMA CORPORATION
To: MITSUBISHI TANABE PHARMA CORPORATION
Reel/Frame 020838/0701 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 22, 2004
From: HOSOKAWA, SAIKO; NIKI, HISAE
To: MITSUBISHI PHARMA CORPORATION
Reel/Frame 015249/0224 →